VISTA Inhibitor

Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research.

Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF.

Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

MS102 is an orally active ubiquitin specific peptidase 2 (USP2) inhibitor with an IC₅₀ of 5.46 μM. MS102 has viable antiviral activity against ACE2-dependent coronaviruses. MS102 significantly reduces V-domain Ig suppressor of T cell activation (VISTA) protein abundance in vitro and in vivo. MS102 can be used for the study of SARS-CoV-2. MS102 can be used in combination with anti-PD-1 immunotherapy to enhance the anti-tumor immune response.

Anti-Mouse VISTA Antibody (8G8) reacts with mouse VISTA. Anti-Mouse VISTA Antibody (8G8) is an agonistic antibody with immunosuppressive properties. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305).

VISTA-IN-1 is an orally active VISTA inhibitor. VISTA-IN-1 inhibits the function of VISTA and promotes the secretion of IL-2. VISTA-IN-1 exerts inhibitory effects on mouse melanoma in vivo. VISTA-IN-1 is applicable to melanoma-related research.

MG-V-53 is a potent small molecule V domain T-cell activating immunoglobulin suppressor (VISTA) inhibitor with IC₅₀ value of 121 nM. MG-V-53 has antitumor activity.

PD-L1/VISTA-IN-2 (Compound S8) is an orally active bifunctional PD-L1/VISTA inhibitor with an IC₅₀ of 1.4 μM for PD-L1 and a K_D of 2.1 μM for VISTA. PD-L1/VISTA-IN-2 can activate the tumor immune microenvironment and exert anti-cancer effects.

PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual-target inhibitor of PD-L1 and VISTA. PD-L1/VISTA-IN-1 can block the PD-1/PD-L1 interaction (IC₅₀: 0.1492 μM) and the VISTA pathway (K_D: 0.2723 μM), thereby reactivating T cells. PD-L1/VISTA-IN-1 has anti-tumor activity.

Anti-VISTA Antibody (GG8) reacts with human VISTA. Endogenous VISTA has inhibitory effects both as a ligand on APCs and as a receptor on T cells. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).

W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research.